Jardiance (Empagliflozin)

Empagliflozin blocks the sodium‑glucose co‑transporter 2 (SGLT2) in the kidney’s proximal tubules, preventing glucose reabsorption. The excess glucose is expelled in the urine, which lowers blood glucose levels and also produces modest diuretic and natriuretic effects that can aid blood‑pressure control.

The dose of Jardiance is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and concomitant therapies. The prescriber determines the appropriate starting dose and any subsequent titration according to current clinical guidelines.

Safety of empagliflozin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To request Jardiance, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Jardiance belongs to the same drug class as canagliflozin, dapagliflozin and ertugliflozin. All share the core mechanism of SGLT2 inhibition, but clinical trials have shown Jardiance to have a robust cardiovascular‑mortality benefit in patients with established cardiovascular disease, a distinction highlighted in its label.

Store Jardiance tablets at ambient temperature, below 25 °C (77 °F). Keep the product in its original blister pack or container, protect it from moisture and direct sunlight, and discard any tablets that are visibly damaged or past the expiry date.

Jardiance is taken orally as a tablet, swallowed whole with a glass of water. It may be taken with or without food, and the dosing schedule (once daily) is set by the prescriber based on the patient’s therapeutic needs.

The most serious risks include diabetic ketoacidosis (which can occur with normal or low blood glucose), acute kidney injury, severe dehydration, and rare but life‑threatening infections such as Fournier’s gangrene. Patients should seek immediate medical attention if they experience symptoms such as nausea, vomiting, abdominal pain, rapid breathing, or unusual genital pain.

Jardiance is contraindicated in patients with a known hypersensitivity to empagliflozin or any component of the formulation, in those with severe renal impairment (eGFR < 30 mL/min/1.73 m²), and in individuals on dialysis. Caution is also advised for patients with a history of recurrent genital or urinary tract infections.